Related Experiment Video
Updated: Jul 11, 2026

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice
Published on: April 10, 2026
BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog
1University of Pittsburgh School of Medicine, Diabetes Institute, Rangos Research Center, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu
Abstract:
F Hoffmann-La Roche Ltd, Teijin Ltd and Chugai Pharmaceutical Co Ltd, under license from Ipsen, are developing the glucagon-like peptide 1 analog BIM-51077, for the potential treatment of type 2 diabetes. Phase II clinical trials are underway, including a phase II trial evaluating a slow release formulation.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Hypoglycemia and Glucagon
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...

